News Archiv

Study demonstrates that Muscular CounterPulsation - the basis of Cardiola's m.pulse^® system - is "safe and efficient for improving cardiac function" non-surgically in patients with coronary artery disease (CAD)

Data presented at the Annual Congress of the Swiss Society of Cardiology (Jun. 23, 2009)
Read more...

Cardiola receives CE Mark recertification and appoints COO and VP Sales

"These events fortify our product roll-out to 4000 cardiologists in Germany and Switzerland, and then subsequent expansion throughout Europe." (Mai 05, 2009)
read more...

Study published in Journal of Cardiac Surgery 

Study demonstrates “therapeutic value of muscular counterpulsation after coronary bypass grafting operation” (Apr. 27, 2009)
read more...

Cardiola raises $2+ million from existing investors

Cash infusion is first tranche of ongoing $7+ million financing round (Apr. 09, 2009)
read more...

European Venture Summit: 2. Platz für Cardiola!

Unter 100 High-Tech-Unternehmen wurde die Cardiola AG als zweitbeste Company ausgezeichnet (Jan, 2009)
read more...

<<zurück